| Added by | llasorsa |
|---|---|
| Group name | EquipeMY |
| Item Type | Journal Article |
| Title | A prospective registry study of stereotactic magnetic resonance guided radiotherapy (MRgRT) for primary liver tumors |
| Creator | Bordeau et al. |
| Author | Karl Bordeau |
| Author | Morgan Michalet |
| Author | Valérie Dorion |
| Author | Aïcha Keskes |
| Author | Simon Valdenaire |
| Author | Pierre Debuire |
| Author | Marie Cantaloube |
| Author | Morgane Cabaillé |
| Author | Roxana Draghici |
| Author | Marc Ychou |
| Author | Eric Assenat |
| Author | Marta Jarlier |
| Author | Sophie Gourgou |
| Author | Boris Guiu |
| Author | Pascal Fenoglietto |
| Author | David Azria |
| Author | Olivier Riou |
| Abstract | BACKGROUND AND PURPOSE: Stereotactic body radiation therapy (SBRT) has demonstrated safe and effective results for primary liver tumors. Magnetic Resonance guided Radiotherapy (MRgRT) is an innovative radiotherapy modality for abdominal tumors. The aim of this study is to report on acute and late toxicities and initial oncological results for primary liver tumors treated with MRgRT. MATERIALS AND METHODS: We prospectively included in our cohort all patients treated by MRgRT for a primary liver tumor at the Montpellier Cancer Institute. The primary endpoint was acute and late toxicities assessed according to CTCAE v 5.0. The mean prescribed dose was 50 Gy in 5 fractions. RESULTS: Between October 2019 and April 2022, MRgRT treated 56 patients for 72 primary liver lesions. No acute or late toxicities of CTCAE grade greater than 2 attributable to radiotherapy were noted during follow-up. No cases of radiation-induced liver disease (RILD), either classical or non-classical, occurred. After a median follow-up of 13.2 months (95% CI [8.8; 15.7]), overall survival was 85.1% (95% CI: [70.8; 92.7]) at 1 year and 74.2% at 18 months (95% CI [52.6; 87.0]). Local control was 98.1% (95% CI: [87.4; 99.7]) and 94.7% (95% CI: [79.5; 98.7]) at 12 and 18 months, respectively. Among the HCC subgroup, no local recurrences were observed. CONCLUSION: MRgRT for primary liver tumors is safe without severe adverse events and reach excellent local control. Numerous studies are underway to better assess the value of MRI guidance and adaptive process in these indications. |
| Publication | Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology |
| Volume | 189 |
| Pages | 109912 |
| Date | 2023-09-20 |
| Journal Abbr | Radiother Oncol |
| Language | eng |
| DOI | 10.1016/j.radonc.2023.109912 |
| ISSN | 1879-0887 |
| Library Catalog | PubMed |
| Extra | PMID: 37739315 |
| Tags | Carcinoma, Hepatocellular, Cholangiocarcinoma, Humans, Liver Neoplasms, Magnetic Resonance guided RadioTherapy (MRgRT), Magnetic Resonance Spectroscopy, Radiosurgery, Radiotherapy, Image-Guided, Stereotatic body radiation therapy (SBRT) |
| Date Added | 2023/11/15 - 14:59:25 |
| Date Modified | 2024/10/10 - 16:27:47 |
| Notes and Attachments | PubMed entry (Attachment) |
Institut de Recherche en Cancérologie de
